Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: First study in Asians

International Journal of Clinical Oncology

Volumn 12, Issue 5, 2007, Pages 341-349

  Aoki, Tomokazu ^a   Nishikawa, Ryo ^b   Mizutani, Tomohiko ^a   Nojima, Kuniharu ^a   Mishima, Kazuhiko ^b   Adachi, Jyunichi ^b   Matsutani, Masao ^b  

^a Kitano Hospital   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Japanese; Malignant gliomas; Pharmacokinetics; Temozolomide

Indexed keywords

5 (3 METHYL) 1 TRIAZEN 1 YLIMIDAZOLE 4 CARBOXAMIDE; IMIDAZOLE DERIVATIVE; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN DAMAGE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DEATH; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLIOBLASTOMA; HUMAN; JAPANESE; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; NAUSEA; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; THROMBOCYTE COUNT;

ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BRAIN NEOPLASMS; DACARBAZINE; DRUG ADMINISTRATION SCHEDULE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS;

EID: 35348871018     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-007-0687-5     Document Type: Article

References (12)

1. JA Slack C Goddard MFG Stevens 1986 The analysis and murine pharmacokinetics of a new antitumor agent: CCRG 81045 J Pharm Pharmacol 38 63
2. RT Wheelhouse MFG Stevens 1993 Decomposition of the antitumor drug temozolomide in deuteruated phosphate buffer: methyl group transfer is accompanied by deuterium exchange J Chem Soc Chem Commun 15 1177 1178
3. BJ Denny RT Wheelhouse MFG Stevens 1994 NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA Biochemistry 33 9045 9051
4. MFG Stevens JA Hickman SP Langdon 1987 Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo [5,1-d]-1,2,3,5- tetrazin-4(3H)-one (CCRG 81045: M&B 39831), a novel drug with potential as an alternative to dacarbazine Cancer Res 47 5846 5852
5. ES Newlands MFG Stevenst SR Wedge 1997 Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials Cancer Treat Rev 23 35 61
6. S Ostermann C Csajka T Buclin 2004 Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients Clin Cancer Res 10 3728 3736
7. ES Newlands GRP Blackledge JA Slack 1992 Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856) Br J Cancer 65 287 291
8. M Brada I Judson P Beale 1999 Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies Br J Cancer 81 1022 1030
9. MA Rudek RC Donehouwer P Statkevich 2004 Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study Pharmacotherapy 24 16 25
10. P Beale I Judson S Moore 1999 Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide Cancer Chemother Pharmacol 44 389 394
11. P Kleihues DN Louis BW Scheithauer 2002 The WHO classification of tumors of the nervous system J Neuropathol Exp Neurol 61 215 225 discussion 226-229
12. LA Hammond JR Eckardt SD Baker 1999 Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies J Clin Oncol 17 2604 2613